Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
AIMS: To test the effect of ivabradine on the outcomes in a broad population with left-ventricular (LV) systolic dysfunction with coronary artery disease (CAD) and/or heart failure (HF). METHODS AND RESULTS: Individual trial data from BEAUTIFUL and SHIFT were pooled to evaluate the effect of ivabradine on the outcomes in patients with LV dysfunction and heart rate ≥ 70 b.p.m. The pooled population (n = 11 897; baseline age 62.3 ± 10.4 years, heart rate 79.6 ± 9.2 b.p.m., and LV ejection fraction 30.3 ± 5.6%) was well treated according to current recommendations (87% beta-blockers, 90% renin-angiotensin system inhibitors). Median follow-up was 21 months. Treatment with ivabradine was associated with a 13% relative risk reduction for the composite of cardiovascular mortality or HF hospitalization (P < 0.001 vs. placebo); this was driven by HF hospitalizations (19%, P < 0.001). There were also significant relative risk reductions for the composite of cardiovascular mortality, HF hospitalizations, or myocardial infarction (MI) hospitalization (15%, P < 0.001); cardiovascular mortality and non-fatal MI (10%, P = 0.023); and MI hospitalization (23%, P = 0.009). Similar results were found in patients with differing clinical profiles. Ivabradine was well tolerated. CONCLUSION: Ivabradine may be important for the improvement of clinical outcomes in patients with LV systolic dysfunction and heart rate ≥ 70 b.p.m., whatever the primary clinical presentation (CAD or HF) or clinical status (NYHA class).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationFox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099 · cited 6×
“was associated with a reduction in the number of patients admitted with myocardial infarction.(6,9) This pooled analysis was limited to patients with elevated heart rate ≥70 b.”
BackgroundMethodSelf-citationResting Heart Rate in Cardiovascular Disease
Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez Sendon, J. L., Steg, P. G., Tardif, J.-C., Tavazzi, L., & Tendera, M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.079 · Cited by 1,062 · cited 2×
“It is also a major determinant of myocardial ischaemia and the development and progression of LV remodelling.(1,2) Elevated heart rate may also be partly responsible for the development of atherogenesis and plaque rupture.”
BackgroundSelf-citationEffect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“The Sibutramine Cardiovascular Outcomes (SCOUT) trial study appeared to confirm this association.(16) Sibutramine, a dopamine analogue known to increase heart rate, was shown to significantly increase the frequency of non-fatal myocardial infarction in a diabetic and coronary disease population, in spite of substantia…”
ResultFox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61171-x · Cited by 789 · cited 4×
“Elevated heart rate is believed to contribute to the development and progression of LV dysfunction, and is associated with higher risk of cardiovascular events.(9,10) It is also a major determinant of myocardial ischaemia and the development and progression of LV remodelling.”
BackgroundResultSelf-citationNatural history of asymptomatic left ventricular systolic dysfunction in the community
Wang, T. J., Evans, J. C., Benjamin, E. J., Levy, D., LeRoy, E. C., & Vasan, R. S. (2003) · Circulation · doi:10.1161/01.cir.0000085166.44904.79 · Cited by 633
Böhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0467-8 · Cited by 248
Self-citation
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations
Boudoulas, K. D., Borer, J. S., & Boudoulas, H. (2015) · Cardiology · doi:10.1159/000435947 · Cited by 1,938
Self-citation
Metadata
- Authors
- Fox, K., Komajda, M., Ford, I., Robertson, M., Böhm, M., Borer, J. S., Steg, P. G., Tavazzi, L., Tendera, M., Ferrari, R., & Swedberg, K.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-03-26
- Volume
- 34
- Issue
- 29
- Pages
- 2263-2270
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2119493017
- Cited by
- 95
- References
- 7
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. https://app.cochat.ai/papers/10.1093/eurheartj/eht101
- The paper
- Fox, K., Komajda, M., Ford, I., Robertson, M., Böhm, M., Borer, J. S., Steg, P. G., Tavazzi, L., Tendera, M., Ferrari, R., & Swedberg, K. (2013). Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal. https://doi.org/10.1093/eurheartj/eht101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.